Company Description
Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.
It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease.
It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2004 |
| IPO Date | Jun 5, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 192 |
| CEO | Ms. Renee Aguiar-Lucander |
Contact Details
Address: Kungsbron 1, D5 Stockholm, V7 SE-111 22 Sweden | |
| Phone | 46 8411 3005 |
| Website | calliditas.se |
Stock Details
| Ticker Symbol | CALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.50 |
| CIK Code | 0001795579 |
| CUSIP Number | 13124Q106 |
| ISIN Number | US13124Q1067 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Renee Aguiar-Lucander | Chief Executive Officer |
| Fredrik Johansson | Chief Financial Officer |
| Dr. Johan Haggblad Ph.D. | Chief Scientific Officer |
| Brian Gorman | Group General Counsel |
| Sandra Frithiof | Head of Human Resources |
| Ann-Kristin Myde BSc | Head of Clinical Development and Vice President of Project Management |
| Dr. Krassimir Mitchev | Head of Medical Affairs |
| Dr. Richard S. Philipson M.D. | Chief Medical Officer |
| Teona Johnson | Head of US Marketing |
| David Ferraro | Head of US Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 24, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 6, 2024 | 6-K | Report of foreign issuer |
| Feb 21, 2024 | 6-K | Report of foreign issuer |
| Jan 8, 2024 | 6-K | Report of foreign issuer |
| Dec 27, 2023 | 6-K | Report of foreign issuer |
| Dec 20, 2023 | 6-K | Report of foreign issuer |
| Dec 11, 2023 | 6-K | Report of foreign issuer |
| Nov 30, 2023 | 6-K | Report of foreign issuer |
| Nov 24, 2023 | 6-K | Report of foreign issuer |